Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Filings indexed 1,189 across all filing types
Latest filing 2018-11-13 Major Shareholding Noti…
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
SEC SCHEDULE 13G
Major Shareholding Notification
2018-11-13 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release about financial results for the third quarter ended September 30, 2018. It also mentions a conference call to discuss these results. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis itself. The length is 3639 characters, which is relatively short and consistent with a current report rather than a full financial report. The document is primarily an announcement of financial results and a conference call, typical of an Earnings Release filing. Therefore, the appropriate classification is Earnings Release (ER).
2018-11-01 English
AMENDMENT NO. 2
Major Shareholding Notification
2018-10-09 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by AtriCure, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures. The document is not an annual or quarterly report, earnings release, or management discussion. It is a capital markets document related to fundraising and issuance of new shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus supplement, not just an announcement or brief notice.
2018-10-05 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 3, 2018, reporting the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. It details the terms of the offering, including the number of shares, pricing, underwriters, and expected proceeds. The document also references press releases announcing the offering and pricing. There are no financial statements or detailed financial performance data included, only the announcement of a financing transaction. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is over 6,000 characters, indicating it is not a mere announcement of a report but the actual filing of the financing event. Therefore, the appropriate classification is CAP with high confidence.
2018-10-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.